BioNTech, UPenn Team up for $50M Seed Fund
BioNTech and the University of Pennsylvania have announced a $50 million seed‑stage venture fund focused on mRNA‑based technologies. The fund will invest in early‑stage biotech startups, leveraging BioNTech’s commercial expertise and UPenn’s research capabilities. By targeting vaccine and therapeutic platforms, the partnership aims to accelerate translation from lab to market. The initiative underscores the growing convergence of academia and industry in the mRNA sector.
Krystal Biotech Says It Can Deliver Native Protein to Cystic Fibrosis Patients
Krystal Biotech announced early data showing its mutation‑agnostic platform can deliver functional native CFTR protein to the lungs of cystic fibrosis patients. In pre‑clinical models, the therapy restored up to 45% of normal chloride transport and reduced inflammatory markers. The...
J&J Strikes Drug Pricing, Tariff Deal with the White House
Johnson & Johnson has become the latest pharmaceutical company to sign a "most‑favored‑nation" pricing agreement with the White House. The deal commits J&J to lower the list prices of a portfolio of high‑cost drugs for federal programs, including Medicare and...
Roche Returns to Chinese Biotech MediLink for Another ADC Pact
Roche has entered a second licensing agreement with Chinese biotech MediLink, this time to develop an antibody‑drug conjugate (ADC) that targets the B7‑H3 antigen on solid tumours. The deal builds on a prior partnership focused on earlier‑stage oncology assets and...
AirNexis Gets $200M to Test China-Derived COPD Drug
AirNexis, a Palo Alto biotech, announced a $200 million financing round to launch clinical testing of a chronic obstructive pulmonary disease (COPD) therapy derived from Chinese research. The capital, sourced from a mix of U.S. and Chinese investors, will fund Phase 2/3...
Speculation Builds About a Deal for Revolution Medicines
Speculation is mounting that Revolution Medicines, a mid‑stage biotech focused on precision oncology, is in advanced talks with one or more large pharmaceutical companies. Media outlets report that the discussions could lead to a takeover or strategic partnership, though no...
Enliven’s Phase 1 Leukemia Pill Data Look Competitive with Novartis and Terns
Enliven Therapeutics announced Phase 1 results for its oral leukemia candidate, showing response rates and safety comparable to leading therapies from Novartis and Terns. The data revealed a 45% overall remission rate and manageable adverse events across 30 patients. The...
Viking Gets Commercial Chief While Other Obesity Biotechs Sell; Novo's Uli Stilz Steps Down
Viking Therapeutics announced the appointment of Neil Aubuchon as its chief commercial officer, signaling a push to accelerate commercialization of its obesity and MASH drug candidates. The move comes as the company’s shareholders grow impatient for a strategic partner or...
Medipost Gets $140M to Take Korean Stem Cell Therapy Into US
Medipost, a Seoul‑area biotech, has secured $140 million to commercialize its allogeneic stem‑cell therapy beyond South Korea. The product, cleared for use in Korea since 2012, will now target the United States and Japan. The capital infusion will fund FDA and...
Gene Editing Pioneers Launch First Startup Focused on Custom CRISPR Therapies
A team of leading gene‑editing scientists has launched a new startup dedicated to developing custom CRISPR therapies for individual patients. The company builds on a landmark case last spring where researchers engineered a bespoke CRISPR treatment to correct a rare...
Aktis Lands Biotech's First IPO of 2026, Raising $318M for Radiopharmaceuticals
Aktis Oncology, a radiopharmaceutical startup co‑founded with Eli Lilly, debuted on Nasdaq, raising $318 million in what is being billed as biotech’s first IPO of 2026. The capital will fund the company’s pipeline of targeted cancer therapies that combine diagnostic imaging with...
OpenAI Brings ChatGPT to Hospitals on the Heels of Launching Consumer Health Tool
OpenAI unveiled ChatGPT for Healthcare, extending its popular conversational AI into hospitals and health systems. The offering follows the recent launch of a consumer‑focused health tool, signaling a broader push into clinical environments. OpenAI says the service will integrate with...
Sanofi Calls Rejection of Potential MS Blockbuster 'Unexpected'
Sanofi announced that the FDA rejected its experimental multiple‑sclerosis therapy, labeling the decision unexpected. The agency raised substantive questions late in the review process, leaving insufficient time for Sanofi to amend its submission. The setback threatens the anticipated launch of...
Illumina Hires Eric Green as Chief Medical Officer
Illumina announced the appointment of Eric Green, former director of the National Human Genome Research Institute and a pioneering geneticist, as its new chief medical officer. Green will lead the company’s clinical strategy, regulatory affairs, and diagnostic product development. The...
Servier Launches VC Unit Focused on European Biotech Startups
Servier has launched a corporate venture‑capital unit with an initial €200 million ($233 million) fund to back European biotech startups. The vehicle will focus on early‑stage companies developing innovative therapeutics that complement Servier’s core therapeutic areas. By providing capital and leveraging its...
FDA Staff Cuts Mostly Didn't Impact New Drug Review Timelines, Analysis Finds
Despite thousands of staff cuts, retirements, and leadership departures at the FDA in 2025, the agency’s drug reviewers largely maintained their review schedules. An internal analysis shows that median approval times for new molecular entities shifted by less than one...
New Lilly Data Suggest Zepbound Boosted Effect of Autoimmune Drug
Eli Lilly’s Phase 3b trial shows its weight‑loss blockbuster Zepbound (tirzepatide) can amplify the efficacy of an existing autoimmune therapy in a targeted patient cohort. The combination yielded superior clinical endpoints compared with the autoimmune drug alone, suggesting a synergistic...
Secretive Rampart Bioscience Closes After Pursuing Non-Viral Gene Therapy
Rampart Bioscience, a stealth biotech founded less than 15 months ago with a $125 million Series A, announced its closure after failing to advance its non‑viral gene‑therapy platform. The company had aimed to address delivery challenges that have limited viral vectors, but...
MoonLake Revives FDA Push; Biotech Trio to Debut in Hong Kong
MoonLake Immunotherapeutics has re‑filed its FDA application for a novel therapy targeting a rare dermatological disorder, aiming to overcome earlier regulatory setbacks. The company highlighted new clinical data showing a 45% improvement in lesion clearance among trial participants. Simultaneously, three...
FDA Drug and Biologic Approvals List 2025: Sign-Offs Dip During Agency Upheaval
The FDA’s 2025 drug and biologic approval tally fell sharply amid a year of internal upheaval. Approvals dropped about 15% compared with 2024, reflecting slower review times as thousands of staff departed and senior leadership changed. The agency’s operational instability...
HHS Loses Bid to Suspend Court Block on 340B Rebate Pilot
The U.S. Department of Health and Human Services (HHS) failed to overturn a federal court order that barred the launch of its 340B rebate pilot. A three‑judge panel of the U.S. Court of Appeals affirmed the lower‑court injunction, keeping the...
Deregulating the Rapidly Evolving Digital Health Industry
The article examines how governments are loosening regulations to accommodate the fast‑moving digital health sector, especially AI‑driven diagnostics and telemedicine. Recent policy proposals aim to streamline FDA approvals, expand data‑sharing frameworks, and create sandboxes for experimental AI tools. OpenAI’s latest...
Charles River CEO Jim Foster to Retire; Samsung Bio Buys a GSK Factory
Charles River Laboratories announced that CEO James C. Foster will retire on May 5 after more than a decade at the helm, and the board has named longtime COO Dr. Laura Miller as his successor. The transition comes as the company seeks...
Ollin’s Drug Clears Retinal Disease Better than Roche’s Vabysmo in Phase 1b Trial
Ollin BioSciences announced Phase 1b data showing its bispecific antibody cleared retinal disease more effectively than Roche's Vabysmo. The early‑stage trial, initiated four months ago, enrolled a modest cohort and reported a favorable safety profile. Efficacy signals suggest superior anatomical...
Inside Doctronic's Experiment to Allow AI to Refill Prescriptions
Doctronic, a digital health platform, launched a pilot that lets an artificial‑intelligence engine automatically refill chronic‑care prescriptions. The AI cross‑checks patient records, insurance eligibility, and dosage guidelines before submitting orders to partner pharmacies. Early data show a 30% reduction in...
Obesity Biotech Alveus Gains $160M for Push Into MariTide's Backyard
Alveus Therapeutics announced a $159.8 million Series A financing round, positioning the obesity‑focused biotech to challenge incumbent players like MariTide. The capital infusion arrives as GLP‑1 agonists tirzepatide and semaglutide dominate pharmacy shelves, spurring a wave of new entrants. Alveus plans to...
Tessera Therapeutics to Lay Off 90 Employees, According to Document
Tessera Therapeutics, a heavily funded gene‑editing startup, announced plans to lay off roughly 90 employees. The cuts represent a significant reduction in its workforce, signaling a shift in the company’s growth trajectory. The layoffs come as the biotech sector faces...
Boltz Raises $28M Seed to Build Open AI Models in Biology
Boltz, a biotech AI startup founded by Gabriele Corso, Jeremy Wohlwend and Saro Passaro, announced a $28 million seed round to develop open‑source artificial‑intelligence models for biology. The capital, sourced from a mix of venture firms and strategic biotech investors, will...
GSK, Noetik Sign Cancer Deal on AI Virtual Cell Models
GlaxoSmithKline (GSK) has entered a multi‑million‑dollar agreement with AI‑driven biotech Noetik to license its virtual cell models for cancer research. The partnership gives GSK access to Noetik’s proprietary AI simulations that predict cellular responses, allowing the pharma giant to evaluate...
Beacon Therapeutics Adds $75M in Push to Succeed Where J&J Failed in Vision Treatment
Beacon Therapeutics announced a $75 million Series C financing round led by Goldman Sachs Alternatives, bolstering its pipeline of gene‑based vision therapies. The capital infusion follows the company’s recent pre‑clinical data showing promise in treating geographic atrophy, a leading cause of blindness....
Parabilis Gets $305M to Tackle ‘Undruggable’ Proteins
Parabilis Medicines announced a $305 million Series B financing round aimed at advancing its platform for targeting so‑called "undruggable" proteins. The capital, led by top venture firms and strategic pharma partners, will fund the development of novel therapeutics against transcription factors and...
Vizgen Raises $48M for Push in Spatial Biology and Multiomics Tools
Vizgen, a spatial biology startup, announced a $48 million Series E round to expand its multi‑omics mapping platform. The funding, led by existing investors, will accelerate product development and scale manufacturing of its high‑resolution gene‑protein co‑detection technology. Vizgen aims to broaden adoption...
French Biotech Enodia Gets €20.7M Aided by Pfizer for Protein Degrader Work
French biotech Enodia Therapeutics announced a €20.7 million financing round, roughly $24 million, to advance its protein degrader platform. The round was led by Pfizer, which provided both capital and strategic support. Enodia, founded in February 2025, aims to develop therapies that...